ANI Pharmaceuticals revenue rises 25.9% to $266M
ANI Pharmaceuticals reported record Q2 2026 net revenue of $266.0 million, up 25.9% year over year. GAAP net income was $24.7 million and adjusted EBITDA rose 32.4% to $71.6 million. Cortrophin Gel revenue grew 43.5% to $117.1 million, but full-year Cortrophin guidance was cut to $520–$540 million. ANIP shares fell 5.53% to $78.06.
How this was made
The 30-second read
Why it matters
Traders may reprice 2026 Cortrophin Gel revenue expectations and reassess whether the acute gout expansion is tracking the prior plan, despite maintained company-wide revenue guidance.
Market read
A guidance cut to the core Cortrophin Gel line is the main incremental catalyst, even as the quarter and full-year revenue outlook remain supportive.
What to watch
The article does not quantify segment margin or cash flow impact from the guidance change, which could be the key driver for longer-duration holders.
Background
ANI Pharmaceuticals reported Q2 2026 results and updated segment-level guidance for Cortrophin Gel while keeping overall revenue outlook unchanged.
Ticker impact
ANI reported record Q2 2026 revenue of $266.0M (+25.9% YoY) and cut Cortrophin Gel 2026 guidance to $520–$540M.
Likely choppy trading, with downside pressure from the guidance reduction despite overall revenue outlook being maintained.
Article cites record Q2 results and maintained full-year revenue guidance, but explicitly lowers Cortrophin Gel guidance and notes shares fell 5.53% to $78.06.
Market effects
Signals potential volatility in specialty pharma growth expectations tied to Cortrophin Gel demand and ramp timing.
Limited, primarily US small/mid-cap biotech sentiment.
Low, no cross-border regulatory or commercial deal details provided.
Counterpoint
The company kept full-year revenue guidance unchanged, suggesting the Cortrophin Gel cut may be offset by other segments or timing rather than demand destruction.
Key entities
- companyANI Pharmaceuticals
Reported record Q2 2026 revenue and lowered Cortrophin Gel 2026 guidance to $520–$540M.
